- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.01. | EXTRAWELL PHAR (00858): NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
| 18.12.23 | EXTRAWELL PHAR (00858): INTERIM REPORT 2023/24 | 1 | HKEx | ||
| 29.11.23 | EXTRAWELL PHAR (00858): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2023 | 1 | HKEx | ||
| 14.11.23 | EXTRAWELL PHAR (00858): DATE OF BOARD MEETING | - | HKEx | ||
| 10.11.23 | EXTRAWELL PHAR (00858): PROFIT WARNING | - | HKEx |
5 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANOCHEMIA PHARMAZEUTIKA | - | - | Nachlese: Magnus Brunner vs. FMA" EOSS holt nach Sanochemia auch BDI BioEnergy; Bettina Pfluger (Christian Drastil) | Um 12:12 liegt der ATX mit +0.03 Prozent im Plus bei 3452 Punkten (Ultimo 2023: 3435, 0.49% ytd). Topperformer der PIR-Group sind Addiko Bank mit +1.82% auf 15.425 Euro, dahinter DO&CO mit +1.79% auf... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 39,040 | +1,01 % | Ionis Pharmaceuticals, Inc.: Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome | - Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events -
-... ► Artikel lesen | |
| CSPC PHARMA | 0,765 | -5,72 % | CSPC PHARMA's US Clinical Trial Application for Highly Selective MAT2A Inhibitor Approved | ||
| SELLAS LIFE SCIENCES | 1,148 | -0,86 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study | - Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Patients Treatment and Follow-Up Without Any Modifications... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 15,845 | +2,13 % | Aktien New York: Indizes bauen Gewinne aus - Inflationsdaten im Fokus | NEW YORK (dpa-AFX) - Die New Yorker Börsen haben nach einem trägen Wochenstart am Dienstag zugelegt. Allerdings reagierten die Aktienkurse erst mit einiger Verzögerung positiv auf US-Inflationsdaten... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 193,75 | +1,31 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH)... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 14,010 | -0,71 % | Santhera Pharmaceuticals Holding AG: Santhera's Partner Catalyst Pharmaceuticals lanciert AGAMREE® (Vamorolon) in den Vereinigten Staaten | AGAMREE® ist von der U.S. FDA zugelassen und jetzt in den USA für die Behandlung von Duchenne-Muskeldystrophie (DMD) bei Patienten ab 2 Jahren erhältlichDies folgt auf die erste kommerzielle Einführung... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,062 | 0,00 % | ENZON PHARMACEUTICALS, INC. - 10-K/A, Annual Report | ||
| OCUPHIRE PHARMA | 1,588 | +6,86 % | Ocuphire Pharma: First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery | LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire's Partner Viatris FARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP)... ► Artikel lesen | |
| DMK PHARMACEUTICALS | 0,049 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.02.2024 - 2 | The following instruments on Boerse Frankfurt do have their last trading day on 13.02.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.02.2024ISIN NameLU0102219945 G.SACHS... ► Artikel lesen | |
| VIRACTA THERAPEUTICS | 0,755 | -0,66 % | Viracta Therapeutics, Inc.: Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | Completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supporting its speed to market strategy; topline results from... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information | Conference Call Scheduled for Thursday, February 15 at 11:30 AM ESTNORTHVALE, NJ / ACCESSWIRE / February 14, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCBB:ELTP), a specialty pharmaceutical... ► Artikel lesen | |
| SAVARA | 4,240 | +0,95 % | Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update | LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 3,240 | -1,82 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update | NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 1,360 | -2,16 % | Biodexa Pharmaceuticals PLC: Biodexa Enters Into Exclusive License to eRapa, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) | April 26, 2024 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Biodexa Enters Into Exclusive License to eRapa, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP)... ► Artikel lesen |
EXTRAWELL PHARMACEUTICAL HOLDINGS LTD gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
